



| | |
|----------------------------|--|
| IACUC | |
| IBC | |
| IRB BIOSECURITY RA | |
| RI COMPLIANCE REGULATORY | |

Three I's: Biosecurity and Research Integrity™: Promoting the Responsible Conduct of Research, Partnership, Ethics, Best Practices and the Exploration of Current Trends

Day 2 **THURSDAY, MAY 2, 2024**

CONFERENCE AGENDA

| | |
|--------------------|---|
| 7:30 AM – 9:00 AM | BREAKFAST MEET-UPS CONFERENCE SPONSORS |
| 9:00 AM | WELCOME TO DAY TWO! |
| 9:00 AM – 11:00 AM | THREE I'S RESEARCH INTEGRITY & ETHICS™ |
| GENERAL SESSION | <p>RESEARCH INTEGRITY, ETHICS AND YOU© a hands-on/interactive session AI IMPACTING RESEARCH ANIMAL TO HUMAN</p> <p>SUSAN N CROPP, PhD CHEMICAL BIOLOGICAL COUNTERMEASURES UNIT/WMDD FBI HEADQUARTERS</p> <p>MINAL M. CARON ROPES & GRAY LLP</p> <p>CECE BROTCHE-FINE, BS, MA, MS, CPIA MODERATOR AD / HEAD AWC CAMBRIDGE NIBR CA IACUC CHAIR & ANIMAL WELFARE OFFICER GLOBAL SCI OPERATIONS / CFO NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.</p> <p>TED MYATT, ScD MODERATOR ASSOCIATE VICE PROVOST OF RESEARCH INTEGRITY TUFTS UNIVERSITY</p> |
| 11:00 AM -11:10 AM | REFRESHMENT BREAK |

| | | | |
|---------------------|---|--|---|
| 11:15 AM – 12:15 PM | ALL I's – Biosecurity – Research Administration – Research Integrity | | |
| | <p>THE LONG ROAD TO DRUG DISCOVERY GAME</p> <p>DR CHANDRA WILLIAMS DIRECTOR, COMPARITIVE MEDICINE PFIZER</p> <p>CYNTHIA FILLIETTAZ, MBA, CPIA, LATG, CVT IACUC ADMINISTRATOR COMPARATIVE MEDICINE PFIZER</p> <p>This session will provide participants with an understanding of how drugs are discovered.</p> <p>The Long Road to Drug Discovery Game is an engaging outreach program designed to provide an interactive and educational experience that sheds light on the complex process of drug discovery and development process. A combination of a slide presentation and a board game gives participants a glimpse into the various steps involved in getting a new medicine on the market while also experiencing the challenges and triumphs along the way. The program encourages critical thinking, teamwork, and problem-solving skills, as teams work to navigate the Drug Development path and launch their own new drug. This outreach program offers a unique opportunity to gain a general understanding of the pharmaceutical industry and the various career opportunities involved in the field. At the end of the program, participants will come away with a newfound appreciation for the complexity of developing new drugs and the significant investment in time, money, and resources that are required to make it happen.</p> | <p>UNINTENTIONAL INTERNAL THREATS TO RESEARCH DATA</p> <p>KELÉ PIPER DIRECTOR, RESEARCH COMPLIANCE OFFICE OF COMPLIANCE MASSACHUSETTS GENERAL HOSPITAL</p> <p>SESSION OBJECTIVES Assess vulnerabilities and risks to research data stemming from institutional practices and attitudes</p> <p>Use data incidents and breaches to improve internal controls for research data</p> <p>Explore and evaluate preventative measures that minimize risk of internal data incidents</p> <p>SESSION DESCRIPTION Data security is a top compliance threat facing organizations. In research, data management and security are challenging with each lab and project having unique data needs and expectations. Researchers are overwhelmed by the volume of data requirements and can inadvertently contribute to data security noncompliance, breaches and other data integrity issues. In this session, we examine ways that researchers contribute to data noncompliance, recognize hotspots and analyze ways to better help researchers comply.</p> | <p>PHOOEY! WE'VE BEEN FOIA'D... NOW WHAT?</p> <p>MICHELLE SCHATZ RESEARCH COMPLIANCE SPECIALIST HARVARD MEDICAL SCHOOL</p> <p>ELEANOR KUSZMAR, MS, CHRC, CRA DIRECTOR FOR RESEARCH COMPLIANCE OFFICE OF ACADEMIC AND RESEARCH INTEGRITY HARVARD MEDICAL SCHOOL</p> <p>Information requests based on information access laws are proliferating in research for many reasons. In this session, we will examine different types of information requests in research and what documents are subject to such requests. Federal, state and local laws that govern information requests will be compared and analyzed. Differences in obligations and risks for public vs private institutions will be discussed. We will demystify exemptions and provide tips on limiting exposure for sensitive research information. Attendees will review sample documents and determine which pieces of information are appropriate to redact. There will be a discussion of current information request cases and we will identify strategies to reduce risk to both institutions and individuals.</p> |
| 12:15 PM – 1:00 PM | LUNCH | | |

| | | | |
|-------------------|--|--|---|
| 1:05 PM – 1:50 PM | | | |
| | <p style="text-align: center;">MANAGING AND SUPPORTING THE USE OF CONTROLLED SUBSTANCES IN NON-CLINICAL RESEARCH</p> <p style="text-align: center;">LAUREN PETER BILH INTEGRITY AND COMPLIANCE</p> <p>How to react to a changing regulatory landscape – rescheduling of drugs, changes in licensing systems, supporting researchers at DEA and State inspections</p> <p>Educational initiatives – turnover is a fact of life in our world. How to ensure new staff is well versed in policies and procedures.</p> <p>Lessons learned from a full audit of users after the COVID shutdown interrupted many checks and balances.</p> | <p style="text-align: center;">TBA</p> <p>FRANK SANGIORGI, PHD MANAGER OF RESEARCH INTEGRITY BRANDEIS UNIVERSITY</p> | <p style="text-align: center;">DONE WRONG—GOTTA PAY: RESEARCH NON-COMPLIANCE AND RESEARCH</p> <p style="text-align: center;">JOHN R BAUMANN, PHD ASSOCIATE VICE PRESIDENT FOR RESEARCH COMPLIANCE INDIANA UNIVERSITY</p> <p>We regularly read about how the identification of unallowable costs may lead to requirements for reimbursement federal and other sponsors of research. Less known, however, are incidents of reimbursement to sponsors due to the identification of misconduct or non-compliance in the conduct of the research. This session will provide an overview of the ‘non-financial’ events that may lead an organization to having to reimburse a sponsor for some or all of the claimed research expenses. More specifically, the panelists will discuss the steps leading to the identification of research non-compliance and/or misconduct (from allegation to determination) and the procedures that an institution may have to undertake to process the reimbursement</p> |
| 1:55 PM – 2:50 PM | GENERAL SESSION | | |
| FBI WMD | <p style="text-align: center;">NEW SCREENING GUIDELINES FOR DNA SYTHESIS Benchtop sequencing vetting tracking</p> <p style="text-align: center;">JOSHUA E CANTER WMD COORDINATOR FBI BOSTON DIVISION</p> | | |
| 2:50 PM – 3:00 PM | REFRESHMENT BREAK | | |

| | | | |
|---|--|-------------------|--|
| 3:00 PM – 4:00 PM | BREAKOUT SESSIONS | | |
| | <p>IACUC CHALLENGES: CASE STUDIES FROM REAL LIFE</p> <p>MARCY BROWN, BS, MA, CMAR, CPIA ANIMAL WELFARE AND IACUC PROGRAM SPECIALIST</p> <p>DEB FROLICHER, DIRECTOR IACUC OFFICE THE SCRIPPS RESEARCH INSTITUTE</p> <p>USDA</p> | <p>TBA</p> | <p>ETHICAL CONUNDRUMS OF CURRENT US FUNDING AGENCY RESEARCH SECURITY EFFORTS</p> <p>STACY PRITT, DVM, MS, MBA, CPIA, CHRC, EXCS, DACAW ASSOCIATE VICE CHANCELLOR CHIEF RESEARCH COMPLIANCE OFFICER THE TEXAS A&M UNIVERSITY SYSTEM</p> <p>Research security became a focal point for US federal agencies funding academic research in 2018 when NIH started sending notifications to dozens of academic institutions about concerns involving foreign influence in research. The effort to determine the scope and extent of the foreign influence started, which started years before 2018, continues today and has culminated in the recent release of draft Research Security Program (RSP) requirements. Lost in this effort are the ethical conundrums presented by the federal government’s shifting requirements, inconsistent responses by academic institutions, and the potential chilling effect that all of this has on international research collaborations. This session will breakdown the concerns US agencies have with inappropriate foreign influence in research, review how those concerns have evolved since 2018, and identify the ethical conundrums inherent to this topic.</p> <p>Learning Objectives:</p> <ol style="list-style-type: none"> 1 - Understand the background and rationale for why US federal funding agencies are concerned with inappropriate foreign influence in research and created the current parameters of research security 2 - Review the changing landscape of research security as it impacts researchers and research institutions 3 - Identify the ethical conundrums researchers and research institutions face when evaluating proposed federal research security requirements |
| SEE YOU IN THE AM FOR BREAKFAST! | | | |